Anti-fibrosis effect of astragaloside IV in animal models of cardiovascular diseases and its mechanisms: a systematic review
Authors:
Open Access
- 22 April 2025
- journal article
- review article
- Published by Taylor & Francis in Pharmaceutical Biology
- Vol. 63 (1) , 250-263
Abstract
Myocardial fibrosis is a common manifestation of end-stage cardiovascular disease, but there is a lack of means to reverse fibrosis. Astragaloside IV (AS-IV), the major active component of Astragalus membranaceus Fisch. ex Bunge Fabaceae, possesses diverse biological activities that have beneficial effects against cardiovascular disease. This systematic review aims to summarize the anti-fibrosis effect of AS-IV in animal models (rats or mice only) and its underlying mechanisms, and provide potential directions for the clinical use of AS-IV. PubMed, EMBASE, Web of Science, CNKI, Wanfang database, and SinoMed were searched from inception to 31 December 2024. The following characteristics of the included studies were extracted and summarized: animal model, route of administration, dose/concentration, measurement indicators, and potential mechanisms. The quality of the included studies was assessed used a 10-item scale from SYRCLE. AS-IV represents a promising multi-target candidate for myocardial fibrosis treatment in the 24 eligible studies included in the analysis. This systematic review is the first to comprehensively evaluate the anti-fibrosis mechanisms of AS-IV across heterogeneous cardiovascular disease animal models, including myocardial infarction, hypertension, ischemia-reperfusion injury, and myocarditis. The underlying mechanisms of the anti-fibrosis effects of AS-IV may include collagen metabolism, anti-apoptosis, anti-inflammation and, pyroptosis, antioxidants, improving mitochondrial function, regulating senescence, etc. Current evidence remains preclinical, with critical gaps in toxicological profiles, human safety thresholds, and clinical adverse reaction data. Future research must integrate robust toxicological evaluations, optimized combination therapies, and adaptive clinical trials to validate translational potential.Keywords
This publication has 54 references indexed in Scilit:
- Matrix metalloproteinase interactions with collagen and elastinMatrix Biology, 2015
- Mechanisms and Functions of InflammasomesCell, 2014
- SYRCLE’s risk of bias tool for animal studiesBMC Medical Research Methodology, 2014
- The pathogenesis of cardiac fibrosisCellular and Molecular Life Sciences, 2013
- Interstitial Collagen CatabolismJournal of Biological Chemistry, 2013
- The Role of the NLRP3 Inflammasome in FibrosisThe Open Rheumatology Journal, 2012
- Astragaloside IV attenuates myocardial fibrosis by inhibiting TGF-β1 signaling in coxsackievirus B3-induced cardiomyopathyEuropean Journal of Pharmacology, 2011
- Immunological aspect of cardiac remodeling: T lymphocyte subsets in inflammation-mediated cardiac fibrosisExperimental and Molecular Pathology, 2011
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLOS Biology, 2010
- Correlations Between the Collagen Content of the Human Left Ventricular Myocardium, Measured by Biochemical and Morphometric MethodsArquivos Brasileiros de Cardiologia, 2002